SAB Biotherapeutics’ DiversitAb novel drug development platform creates targeted fully human multi-epitope binding immunoglobulins (polyclonal antibodies) without the need for human donors. Its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback